Cell line · CVCL_0393

LN-229

Cancer cell line, Homo sapiens. Glioblastoma. 104 papers.

4 sourcescell-lines-2026-11-14-0.1.0

Cite this record

ConductScience Library. LN-229. Cell lines, record CVCL_0393. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0393

On this page

Cell line

As Cellosaurus gives it.

Name: LN-229
Accession: CVCL_0393
RRID: RRID:CVCL_0393
Synonyms: LN 229, LN229, LNT-229
Species: Homo sapiens (Human)
Sex: Female
Age at sampling: 60Y
Category: Cancer cell line
Diseases: Glioblastoma (NCIt C3058); Glioblastoma (ORDO Orphanet_360)
Derived from: Brain, right frontal parieto-occipital cortex (in situ)
Entry created: 2012-04-04
Entry updated: 2026-06-25

Source Cellosaurus

Problems0

Cellosaurus records no problem for this cell line.

None in this release.

Papers104

Paper	Journal	Year	How we know	Source
Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption.	Adv Sci (Weinh)	2026	Its Methods give the RRID and name the line	PubMed
LRIG2 suppresses NK cell-induced GSDME-mediated pyroptosis via the LAMP1-STAT3 pathway in glioma.	J Immunother Cancer	2026	Its Methods give the RRID and name the line	PubMed
Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.	Oncogene	2026	Its Methods give the RRID and name the line	PubMed
COPS7B Drives Malignant Progression of Glioblastoma Through Translational Upregulation of the Downstream Functional Effector CLU.	Int J Mol Sci	2026	Its Methods give the RRID and name the line	PubMed
Exploring Disulfide Bridge as a Tool to Improve Pioglitazone's Neuroprotective Potential: Toward the Development of Prolonged-Acting MAO-B/PPARγ Modulators.	ChemMedChem	2026	Its Methods give the RRID and name the line	PubMed
Potent Anti-Glioblastoma Effects of Next-Generation MNK Inhibitors.	Cancers (Basel)	2026	Its Methods give the RRID and name the line	PubMed
Uncovering MYOF as a novel therapeutic target in glioblastoma: mechanistic insights and drug discovery.	Cell Death Discov	2026	Its Methods give the RRID and name the line	PubMed
Feasibility and optimal imaging time window for intraperitoneal versus intravenous injection of a macrocyclic gadolinium-based contrast agent in mice.	J Int Med Res	2026	Its Methods give the RRID and name the line	PubMed
Hypoxia-induced circSPECC1 drives temozolomide resistance in glioblastoma via IGF2BP2-mediated PGK1 mRNA stabilization.	Cell Death Dis	2026	Its Methods give the RRID and name the line	PubMed
CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair.	Genes Dis	2026	Its Methods give the RRID and name the line	PubMed

1 to 10 of 104

See all 104 papers

Relatives23

Relation	Cell line	Accession	Source
Derived from it	HyCyte LN-229 KO-hAP1S1	CVCL_F1RD	Cell lines
Derived from it	HyCyte LN-229 KO-hSMARCAL1	CVCL_F1RE	Cell lines
Derived from it	LN-229-EGFP	CVCL_D7FE	Cell lines
Derived from it	LN-229-Luc	CVCL_D7FD	Cell lines
Derived from it	LN-229_indWIF1	CVCL_WS33	Cell lines
Derived from it	LN229-CHID1	CVCL_E8NR	Cell lines
Derived from it	LN229/CD133	CVCL_D2RW	Cell lines
Derived from it	LN229/CD19	CVCL_D2TH	Cell lines
Derived from it	LN229/CD19ec	CVCL_D2TI	Cell lines
Derived from it	LN229/CD20	CVCL_A8V5	Cell lines

1 to 10 of 23

See all 23 relatives

Cell banks5

Cell bank	Catalog number	Source
ATCC	CRL-2611	ATCC
AddexBio	C0005017/4993	Cellosaurus
CLS	305043	CLS
Hysigen	TCH-C387	Hysigen
Ubigene	YC-A021	Ubigene

Data dates

The date of each source this release read.

Cellosaurus: 2026-10-22; Cellosaurus
PubMed Central's articles: 2026-11-12; PubMed Central's articles
Our copy of PubMed: 2026-11-06; Our copy of PubMed

Sources 4

CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
PubMedNLM's terms

Each source's terms

CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this cell line from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_0393

GET https://conductscience.org/api/cell-lines/v1/CVCL_0393/papers?page=2

API reference For AI assistants